{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:04:25Z","timestamp":1791921865606,"version":"4.3.4"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.vhri.2023.04.004","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T02:44:31Z","timestamp":1686883471000},"page":"71-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Soroush Ahmadi","family":"Fariman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Jahangard Rafsanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Hasanzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia","family":"Niksalehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekoufeh","family":"Nikfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.vhri.2023.04.004_bib1","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.18632\/oncotarget.26909","article-title":"Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses","volume":"10","author":"Henderson","year":"2019","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.vhri.2023.04.004_bib2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/annonc\/mdz044","article-title":"Meeting report from the joint IARC-NCI international cancer seminar series: a focus on colorectal cancer","volume":"30","author":"Gunter","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2023.04.004_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12962-022-00339-2","article-title":"Treatment pathways and associated costs of metastatic colorectal cancer in Greece","volume":"20","author":"Sougklakos","year":"2022","journal-title":"Cost Eff Resour Alloc"},{"issue":"5707","key":"10.1016\/j.vhri.2023.04.004_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.2.5707.469","article-title":"ABC of colorectal cancer: treatment of the advanced disease","volume":"2","author":"Young","year":"1970","journal-title":"BMJ"},{"key":"10.1016\/j.vhri.2023.04.004_bib5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JGO.19.00367","article-title":"Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline","volume":"6","author":"Chiorean","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"6","key":"10.1016\/j.vhri.2023.04.004_bib6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdn735","article-title":"Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel","volume":"20","author":"Nordlinger","year":"2009","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.vhri.2023.04.004_bib7","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.vhri.2023.04.004_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2018.11.010","article-title":"A\u00a0cost analysis of upfront DPYD genotype\u2013guided dose individualisation in fluoropyrimidine-based anticancer therapy","volume":"107","author":"Henricks","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.vhri.2023.04.004_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"(CPIC) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.vhri.2023.04.004_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.vhri.2023.04.004_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/2042098613485595","article-title":"Pharmacogenetic testing: current evidence of clinical utility","volume":"4","author":"Moaddeb","year":"2013","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"10.1016\/j.vhri.2023.04.004_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12885-022-09171-6","article-title":"Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation","volume":"22","author":"Lau-Min","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vhri.2023.04.004_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2015.11.008","article-title":"Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time","volume":"54","author":"Lunenburg","year":"2016","journal-title":"Eur J Cancer"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2023.04.004_bib14","first-page":"1","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"J\u00a0Med Econ"},{"issue":"12","key":"10.1016\/j.vhri.2023.04.004_bib15","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value health"},{"issue":"4","key":"10.1016\/j.vhri.2023.04.004_bib16","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cpt.1257","article-title":"The genotype for DPYD risk variants in patients with colorectal cancer and the related toxicity management costs in clinical practice","volume":"105","author":"Toffoli","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"28","key":"10.1016\/j.vhri.2023.04.004_bib17","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1200\/JCO.2008.17.1249","article-title":"Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma","volume":"26","author":"Haller","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"10.1016\/j.vhri.2023.04.004_bib18","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1200\/JCO.2008.17.7147","article-title":"Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741","volume":"26","author":"Sanoff","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.vhri.2023.04.004_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2018.07.138","article-title":"Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers","volume":"104","author":"Lunenburg","year":"2018","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.vhri.2023.04.004_bib20","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.vhri.2023.04.004_bib21","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","article-title":"DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update","volume":"28","author":"Henricks","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2023.04.004_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD\u22172A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2023.04.004_bib23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021","volume":"19","author":"Benson","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.vhri.2023.04.004_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.630456","article-title":"Characteristics and absolute survival of metastatic colorectal cancer patients treated with biologics: a real-world data analysis from three European countries","volume":"11","author":"Oppelt","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.vhri.2023.04.004_bib25","first-page":"170","article-title":"Occurrence and management of thrombocytopenia in metastatic colorectal cancer patients receiving chemotherapy: secondary analysis of data from prospective clinical trials","volume":"20","author":"Kilpatrick","year":"2021","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.vhri.2023.04.004_bib26","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"issue":"suppl 5","key":"10.1016\/j.vhri.2023.04.004_bib27","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/j.vhri.2023.04.004_bib28","doi-asserted-by":"crossref","first-page":"iv126","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2023.04.004_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JOP.19.00652","article-title":"Management of cancer therapy\u2013associated oral mucositis","volume":"16","author":"Brown","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.vhri.2023.04.004_bib30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol Rev"},{"issue":"32","key":"10.1016\/j.vhri.2023.04.004_bib31","first-page":"3825","article-title":"Antiemetics: ASCO guideline update [published correction appears in","volume":"38","author":"Hesketh","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.vhri.2023.04.004_bib32","author":"van Rhee"},{"issue":"2","key":"10.1016\/j.vhri.2023.04.004_bib33","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S1470-2045(19)30010-5","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors\u2019 reply","volume":"20","author":"Henricks","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.vhri.2023.04.004_bib34","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/ijc.32022","article-title":"Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD\u22172A variant: a matched pair analysis","volume":"144","author":"Henricks","year":"2019","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.vhri.2023.04.004_bib36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"issue":"10","key":"10.1016\/j.vhri.2023.04.004_bib37","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bjc.2011.409","article-title":"Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment","volume":"105","author":"Bennett","year":"2011","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.vhri.2023.04.004_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.bjc.6605114","article-title":"Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials","volume":"101","author":"Shiroiwa","year":"2009","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.vhri.2023.04.004_bib39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12955-018-0994-8","article-title":"Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients","volume":"16","author":"Paracha","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"34","key":"10.1016\/j.vhri.2023.04.004_bib40","first-page":"135","article-title":"Estimation of social discount rate for Iran","volume":"9","author":"Abdoli","year":"2009","journal-title":"Econ Res"},{"issue":"4","key":"10.1016\/j.vhri.2023.04.004_bib41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1089\/gtmb.2020.0285","article-title":"DPYD c.1905\u00a0+ 1G>A Promotes fluoropyrimidine-induced anemia, a prognostic factor in disease-free survival, in colorectal cancer","volume":"25","author":"Deligonul","year":"2021","journal-title":"Genet Test Mol Biomarkers"},{"issue":"1","key":"10.1016\/j.vhri.2023.04.004_bib42","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12885-020-06904-3","article-title":"Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients","volume":"20","author":"Negarandeh","year":"2020","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.vhri.2023.04.004_bib43","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1158\/1078-0432.CCR-10-2209","article-title":"Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer","volume":"17","author":"Deenen","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.vhri.2023.04.004_bib44","first-page":"870","article-title":"Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients","volume":"38","author":"Kristensen","year":"2010","journal-title":"J\u00a0Int Med Res"},{"issue":"33","key":"10.1016\/j.vhri.2023.04.004_bib45","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1200\/JCO.2008.21.6283","article-title":"Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial","volume":"27","author":"Braun","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.vhri.2023.04.004_bib46","first-page":"238","article-title":"5-fluorouracil toxicity-attributable IVS14\u00a0+ 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients","volume":"60","author":"Sulzyc-Bielicka","year":"2008","journal-title":"Pharmacol Rep"},{"issue":"2","key":"10.1016\/j.vhri.2023.04.004_bib47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.vhri.2023.04.004_bib48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.GIM.0000118061.66602.A5","article-title":"Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluorouracil toxicity in Portuguese colorectal cancer patients","volume":"6","author":"Salgueiro","year":"2004","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.vhri.2023.04.004_bib49","doi-asserted-by":"crossref","first-page":"7859","DOI":"10.18632\/oncotarget.23559","article-title":"DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer","volume":"9","author":"Cremolini","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.vhri.2023.04.004_bib50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00280-017-3478-3","article-title":"DPYD\u22172A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer","volume":"81","author":"Nahid","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.vhri.2023.04.004_bib51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2018.07.009","article-title":"Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy","volume":"102","author":"Madi","year":"2018","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.vhri.2023.04.004_bib52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FPC.0000000000000197","article-title":"Association between DPYD c.1129-5923 C>G\/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)","volume":"26","author":"Lee","year":"2016","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"10.1016\/j.vhri.2023.04.004_bib53","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2013.53.4479","article-title":"Genetic biomarkers for fluorouracil toxicity prediction: the long road to clinical utility","volume":"32","author":"Lee","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.vhri.2023.04.004_bib54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaoncol.2015.5392","article-title":"DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial","volume":"2","author":"Boige","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2023.04.004_bib55","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bcp.12631","article-title":"DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan","volume":"80","author":"Falvella","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.vhri.2023.04.004_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124893","article-title":"Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines [published correction appears in","volume":"10","author":"Jennings","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vhri.2023.04.004_bib57","doi-asserted-by":"crossref","first-page":"dju298","DOI":"10.1093\/jnci\/dju298","article-title":"DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)","volume":"106","author":"Lee","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.vhri.2023.04.004_bib58","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/cts.12981","article-title":"Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events","volume":"14","author":"Wigle","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.vhri.2023.04.004_bib59","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/CAD.0000000000000748","article-title":"Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study","volume":"30","author":"Kleinjan","year":"2019","journal-title":"Anticancer Drugs"},{"issue":"9","key":"10.1016\/j.vhri.2023.04.004_bib60","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s12325-016-0376-8","article-title":"Cost-effectiveness of pharmacogenomic and pharmacogenetic test-guided personalized therapies: a systematic review of the approved active substances for personalized medicine in Germany","volume":"33","author":"Pl\u00f6thner","year":"2016","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.vhri.2023.04.004_bib61","first-page":"e189","article-title":"Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based adjuvant chemotherapy for colon cancer","volume":"21","author":"Brooks","year":"2022","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.vhri.2023.04.004_bib62","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/0284186X.2015.1053983","article-title":"The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance","volume":"55","author":"Butzke","year":"2016","journal-title":"Acta Oncol"},{"issue":"9","key":"10.1016\/j.vhri.2023.04.004_bib63","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/pgs-2016-0006","article-title":"Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines","volume":"17","author":"Cortejoso","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.vhri.2023.04.004_bib64","doi-asserted-by":"crossref","DOI":"10.1177\/1559325818803042","article-title":"Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: a single-institution experience","volume":"16","author":"Murphy","year":"2018","journal-title":"Dose-Response"},{"issue":"6","key":"10.1016\/j.vhri.2023.04.004_bib65","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ajhg.2019.04.017","article-title":"Estimating the effectiveness of DPYD genotyping in Italian individuals suffering from cancer based on the cost of chemotherapy-induced toxicity","volume":"104","author":"Fragoulakis","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.vhri.2023.04.004_bib66","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/pon.5054","article-title":"Quality of life versus length of life considerations in cancer patients: a systematic literature review","volume":"28","author":"Shrestha","year":"2019","journal-title":"Psychooncology"},{"issue":"12","key":"10.1016\/j.vhri.2023.04.004_bib67","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/cncr.23968","article-title":"Cancer patient preferences for quality and length of life","volume":"113","author":"Meropol","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.vhri.2023.04.004_bib68","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0272989X14551638","article-title":"Where is the evidence? A systematic review of shared decision making and patient outcomes","volume":"35","author":"Shay","year":"2015","journal-title":"Med Decis Making"},{"issue":"16","key":"10.1016\/j.vhri.2023.04.004_bib69","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.vhri.2023.04.004_bib70","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report","volume":"12","author":"Drummond","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.04.004_bib71","first-page":"1603","article-title":"Ethnic diversity of DPD activity and the DPYD gene: review of the literature","volume":"14","author":"White","year":"2021","journal-title":"Pharmgenomics Pers Med"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923000444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923000444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:14:54Z","timestamp":1761941694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109923000444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":70,"alternative-id":["S2212109923000444"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2023.04.004","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2023.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}